trending Market Intelligence /marketintelligence/en/news-insights/trending/roPZ8KuHcct2C2NEawm1vA2 content esgSubNav
In This List

Cue Biopharma plans to list on Nasdaq

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cue Biopharma plans to list on Nasdaq

Cue Biopharma Inc. intends to launch an IPO on the Nasdaq Capital Market.

The company plans to offer up to 8,333,333 common shares with 0.1 cent par value at a public offering price of between $6 and $8 per share. The company expects to raise proceeds of up to $50 million.

It will be listed on the Nasdaq Capital Market under the ticker CUE.

Cue Biopharma is a Cambridge, Mass.-based preclinical stage biopharmaceutical company that develops biologic drugs to treat various cancers and autoimmune disorders.

MDB Capital Group LLC and Feltl and Co. Inc. serve as underwriters in the offering.